Connor Clark & Lunn Investment Management Ltd. bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 110,353 shares of the company's stock, valued at approximately $58,442,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.40% of Medpace at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in MEDP. BlackRock Inc. acquired a new stake in Medpace in the second quarter valued at approximately $1,323,047,000. AQR Capital Management LLC increased its holdings in shares of Medpace by 31.6% during the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company's stock valued at $758,061,000 after acquiring an additional 324,293 shares in the last quarter. Wasatch Advisors LP raised its position in shares of Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company's stock worth $296,853,000 after purchasing an additional 116,354 shares during the period. Geode Capital Management LLC raised its position in shares of Medpace by 3.8% during the fourth quarter. Geode Capital Management LLC now owns 667,298 shares of the company's stock worth $374,836,000 after purchasing an additional 24,625 shares during the period. Finally, Invesco Ltd. lifted its holdings in shares of Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company's stock worth $276,313,000 after purchasing an additional 85,517 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Medpace
In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm's stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the completion of the sale, the general counsel directly owned 20,343 shares of the company's stock, valued at $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Brian T. Carley sold 5,000 shares of Medpace stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total value of $3,043,150.00. Following the sale, the director owned 27,825 shares in the company, valued at $16,935,129.75. The trade was a 15.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 122,261 shares of company stock worth $71,729,129. Company insiders own 20.50% of the company's stock.
Medpace Price Performance
Shares of NASDAQ MEDP opened at $620.75 on Monday. The company has a market capitalization of $17.33 billion, a PE ratio of 36.39, a PEG ratio of 2.77 and a beta of 1.15. The stock's 50 day moving average price is $550.16 and its 200-day moving average price is $492.03. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90.
Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, beating analysts' consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a return on equity of 110.15% and a net margin of 17.67%.Medpace's revenue was up 17.2% on a year-over-year basis. During the same period last year, the business posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.
Analyst Ratings Changes
Several research firms recently issued reports on MEDP. Weiss Ratings raised shares of Medpace from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 12th. BMO Capital Markets upped their price objective on shares of Medpace from $400.00 to $600.00 and gave the stock a "market perform" rating in a report on Friday, July 24th. Truist Financial raised their price objective on shares of Medpace from $462.00 to $609.00 and gave the company a "hold" rating in a research note on Friday, July 24th. Leerink Partners set a $620.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Finally, Jefferies Financial Group lowered shares of Medpace from a "buy" rating to a "hold" rating and upped their target price for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $584.18.
Check Out Our Latest Research Report on MEDP
About Medpace
(
Free Report)
Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Medpace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.
While Medpace currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
